{"id":45479,"date":"2022-06-24T15:01:45","date_gmt":"2022-06-24T13:01:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/"},"modified":"2022-06-24T15:01:45","modified_gmt":"2022-06-24T13:01:45","slug":"global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/","title":{"rendered":"Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4636693\/global-biosimilars-partnering-terms-and?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=fn9hmn&amp;utm_campaign=1718434+-+Global+Biosimilars+Partnering+Terms+and+Agreements+2010+to+2022%3A+Featuring+Boston+Oncology%2C++Concord+Biosciences%2C+Horizon+2020+%26+More&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Global Biosimilars Partnering Terms and Agreements 2010 to 2022&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220624005246\/en\/1496401\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220624005246\/en\/1496401\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis report is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide.\n<\/p>\n<p>\nThe report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.\n<\/p>\n<p>\nUnderstanding the flexibility of a prospective partner&#8217;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered &#8211; contract documents provide this insight where press releases and databases do not.\n<\/p>\n<p>\nThis report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner&#8217;s flexibility on a wide range of important issues, many of which will have a significant impact on each party&#8217;s ability to derive value from the deal.\n<\/p>\n<p>\n<strong>Global Biosimilars Partnering Terms and Agreements 2010 to 2022 includes:<\/strong>\n<\/p>\n<ul>\n<li>\nTrends in Biosimilars dealmaking in the biopharma industry since 2010\n<\/li>\n<li>\nAccess to headline, upfront, milestone and royalty data\n<\/li>\n<li>\nAccess to over 190 Biosimilars deal records and contract documents where available\n<\/li>\n<li>\nThe leading Biosimilar deals by value since 2010\n<\/li>\n<li>\nMost active Biosimilars dealmakers since 2010\n<\/li>\n<li>\nThe leading Biosimilars partnering resources\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>Executive Summary<\/strong>\n<\/p>\n<p>\n<strong>Chapter 1 &#8211; Introduction<\/strong>\n<\/p>\n<p>\n<strong>Chapter 2 &#8211; Trends in Biosimilars dealmaking<\/strong>\n<\/p>\n<p>\n2.1. Introduction\n<\/p>\n<p>\n2.2. Biosimilars partnering over the years\n<\/p>\n<p>\n2.3. Most active biosimilars dealmakers\n<\/p>\n<p>\n2.4. Biosimilars partnering by deal type\n<\/p>\n<p>\n2.5. Biosimilars partnering by therapy area\n<\/p>\n<p>\n2.6. Deal terms for biosimilars partnering\n<\/p>\n<p>\n2.6.1 Biosimilars partnering headline values\n<\/p>\n<p>\n2.6.2 Biosimilars deal upfront payments\n<\/p>\n<p>\n2.6.3 Biosimilars deal milestone payments\n<\/p>\n<p>\n2.6.4 Biosimilars royalty rates\n<\/p>\n<p>\n<strong>Chapter 3 &#8211; Leading Biosimilars deals<\/strong>\n<\/p>\n<p>\n3.1. Introduction\n<\/p>\n<p>\n3.2. Top Biosimilars deals by value\n<\/p>\n<p>\n<strong>Chapter 4 &#8211; Most active Biosimilars dealmakers<\/strong>\n<\/p>\n<p>\n4.1. Introduction\n<\/p>\n<p>\n4.2. Most active Biosimilars dealmakers\n<\/p>\n<p>\n4.3. Most active Biosimilars partnering company profiles\n<\/p>\n<p>\n<strong>Chapter 5 &#8211; Biosimilars contracts dealmaking directory<\/strong>\n<\/p>\n<p>\n5.1. Introduction\n<\/p>\n<p>\n5.2. Biosimilars contracts dealmaking directory\n<\/p>\n<p>\n<strong>Chapter 6 &#8211; Biosimilars dealmaking by technology type<\/strong>\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\n3SBio\n<\/li>\n<li>\n180 Life Sciences\n<\/li>\n<li>\nAbbvie\n<\/li>\n<li>\nAbreos Biosciences\n<\/li>\n<li>\nAbzena\n<\/li>\n<li>\nAccord Healthcare\n<\/li>\n<li>\nAceno Biotherapeutics\n<\/li>\n<li>\nAdAlta\n<\/li>\n<li>\nAET Biotech\n<\/li>\n<li>\nAetos Biologics\n<\/li>\n<li>\nAffaMed Therapeutics\n<\/li>\n<li>\nAgila Specialties\n<\/li>\n<li>\nAIT Bioscience\n<\/li>\n<li>\nAlgorithme Pharma Holdings\n<\/li>\n<li>\nAlteogen\n<\/li>\n<li>\nAltiora\n<\/li>\n<li>\nAlvogen\n<\/li>\n<li>\nAlvotech\n<\/li>\n<li>\nAmedica\n<\/li>\n<li>\nAmgen\n<\/li>\n<li>\nAmneal Pharmaceuticals\n<\/li>\n<li>\nArecor\n<\/li>\n<li>\nAvid Bioservices\n<\/li>\n<li>\nAxantia\n<\/li>\n<li>\nBack-A-Line\n<\/li>\n<li>\nBacterin International\n<\/li>\n<li>\nBaxalta\n<\/li>\n<li>\nBaxter International\n<\/li>\n<li>\nBeiGene\n<\/li>\n<li>\nBio-Manguinhos\/Fiocruz\n<\/li>\n<li>\nBio-Thera Solutions\n<\/li>\n<li>\nBiocnd\n<\/li>\n<li>\nBiocon\n<\/li>\n<li>\nBioeq IP\n<\/li>\n<li>\nBio Farma\n<\/li>\n<li>\nBiogen\n<\/li>\n<li>\nBiooutsource\n<\/li>\n<li>\nBiosanaPharma\n<\/li>\n<li>\nBioSavita\n<\/li>\n<li>\nBioSciencesCorp\n<\/li>\n<li>\nBioton\n<\/li>\n<li>\nBioXpress\n<\/li>\n<li>\nBoehringer Ingelheim\n<\/li>\n<li>\nBolt Biotherapeutics\n<\/li>\n<li>\nBoston Oncology\n<\/li>\n<li>\nBruker\n<\/li>\n<li>\nC-Bridge Capital\n<\/li>\n<li>\nCatalent\n<\/li>\n<li>\nCEA-Leti\n<\/li>\n<li>\nCelares\n<\/li>\n<li>\nCelerion\n<\/li>\n<li>\nCellectis\n<\/li>\n<li>\nCelltrion\n<\/li>\n<li>\nChangchun High &amp; New Technology Industries\n<\/li>\n<li>\nChemo Sa Lugano\n<\/li>\n<li>\nChungnam National University\n<\/li>\n<li>\nCipla\n<\/li>\n<li>\nCJ Corp\n<\/li>\n<li>\nClinigen\n<\/li>\n<li>\nCobra Biologics\n<\/li>\n<li>\nCoherus Biosciences\n<\/li>\n<li>\nCompass Biotechnologies\n<\/li>\n<li>\nConcord Biosciences\n<\/li>\n<li>\nCook Pharmica\n<\/li>\n<li>\nCR Pharma\n<\/li>\n<li>\nDaiichi Sankyo\n<\/li>\n<li>\nDiabeloop\n<\/li>\n<li>\nDM Corporation\n<\/li>\n<li>\nDong-A ST\n<\/li>\n<li>\nDr. Reddy&#8217;s Laboratories\n<\/li>\n<li>\nDyadic International\n<\/li>\n<li>\nEirGenix\n<\/li>\n<li>\nEMD Millipore\n<\/li>\n<li>\nEnzene Biosciences\n<\/li>\n<li>\nEpirus Biopharmaceuticals\n<\/li>\n<li>\nEpivax\n<\/li>\n<li>\nEuropean Commission\n<\/li>\n<li>\nEvercyte\n<\/li>\n<li>\nEvotec\n<\/li>\n<li>\nEwopharma\n<\/li>\n<li>\nFormosa Pharmaceuticals\n<\/li>\n<li>\nFormycon\n<\/li>\n<li>\nFujifilm\n<\/li>\n<li>\nFujifilm Kyowa Kirin Biologics\n<\/li>\n<li>\nFuji Pharma\n<\/li>\n<li>\nGC Pharma\n<\/li>\n<li>\nGedeon Richter\n<\/li>\n<li>\nGE Healthcare\n<\/li>\n<li>\nGenentech\n<\/li>\n<li>\nGenhelix Biopharmaceutical\n<\/li>\n<li>\nGenor Biopharma\n<\/li>\n<li>\nGenScript ProBio\n<\/li>\n<li>\nGerresheimer\n<\/li>\n<li>\nHadasit Medical Research Services and Development\n<\/li>\n<li>\nHanwha Chemical\n<\/li>\n<li>\nHelvetic Biopharma\n<\/li>\n<li>\nHenlius Biotech\n<\/li>\n<li>\nHikma Pharmaceuticals\n<\/li>\n<li>\nHoffmann La Roche\n<\/li>\n<li>\nHorizon 2020\n<\/li>\n<li>\nHospira\n<\/li>\n<li>\nInnovent Biologics\n<\/li>\n<li>\nIntas Pharmaceuticals\n<\/li>\n<li>\ninVentiv Health\n<\/li>\n<li>\nIpca Laboratories\n<\/li>\n<li>\nIpsen\n<\/li>\n<li>\nJacobson Pharma\n<\/li>\n<li>\nJAMP Pharma Group\n<\/li>\n<li>\nJHL Biotech\n<\/li>\n<li>\nKamada\n<\/li>\n<li>\nKarolinska Institute\n<\/li>\n<li>\nKemwell BioPharma\n<\/li>\n<li>\nKymos Pharma Services\n<\/li>\n<li>\nKyowa Hakko Kirin\n<\/li>\n<li>\nLaboratorios Liomont\n<\/li>\n<li>\nLABORATORIOS SAVAL\n<\/li>\n<li>\nLigacept\n<\/li>\n<li>\nLivzon Mabpharm\n<\/li>\n<li>\nLupin\n<\/li>\n<li>\nM+W Group\n<\/li>\n<li>\nMab-Venture Biopharma\n<\/li>\n<li>\nMabion\n<\/li>\n<li>\nmAbXience\n<\/li>\n<li>\nMedicago\n<\/li>\n<li>\nMedicure\n<\/li>\n<li>\nMedipolis\n<\/li>\n<li>\nMeiji Seika\n<\/li>\n<li>\nMerck and Co\n<\/li>\n<li>\nMerck BioVentures\n<\/li>\n<li>\nMerck KGaA\n<\/li>\n<li>\nMerck Serono\n<\/li>\n<li>\nMGC Diagnostics\n<\/li>\n<li>\nMinistry of Health (Brazil)\n<\/li>\n<li>\nMithra Pharmaceuticals\n<\/li>\n<li>\nMitsubishi Chemical\n<\/li>\n<li>\nMochida Pharmaceutical\n<\/li>\n<li>\nMomenta Pharmaceuticals\n<\/li>\n<li>\nMundipharma\n<\/li>\n<li>\nMylan Laboratories\n<\/li>\n<li>\nMylan Pharmaceuticals\n<\/li>\n<li>\nNan Fung Group\n<\/li>\n<li>\nNanoLock\n<\/li>\n<li>\nNatco Pharmaceuticals\n<\/li>\n<li>\nNational Cancer Institute\n<\/li>\n<li>\nNational Comprehensive Cancer Network (NCCN)\n<\/li>\n<li>\nNCPC GeneTech\n<\/li>\n<li>\nNeoletix Biotechnology\n<\/li>\n<li>\nNeuClone\n<\/li>\n<li>\nNora Pharma\n<\/li>\n<li>\nNovo Nordisk\n<\/li>\n<li>\nOcumension Therapeutics\n<\/li>\n<li>\nOncobiologics\n<\/li>\n<li>\nORF Genetics\n<\/li>\n<li>\nOrox Pharmaceuticals\n<\/li>\n<li>\nOrygen Biotecnologia\n<\/li>\n<li>\nPall Corporation\n<\/li>\n<li>\nPangen Biotech\n<\/li>\n<li>\nParexel\n<\/li>\n<li>\nPBS Biotech\n<\/li>\n<li>\nPerfinity Biosciences\n<\/li>\n<li>\nPfenex\n<\/li>\n<li>\nPfizer\n<\/li>\n<li>\nPharmapark\n<\/li>\n<li>\nPharmaPraxis\n<\/li>\n<li>\nPlantForm\n<\/li>\n<li>\nPlantPraxis Biotecnologia\n<\/li>\n<li>\nPolpharma\n<\/li>\n<li>\nPortal Instruments\n<\/li>\n<li>\nPPD\n<\/li>\n<li>\nPRA Health Sciences\n<\/li>\n<li>\nPremier Inc\n<\/li>\n<li>\nPremier Research\n<\/li>\n<li>\nPrestige BioPharma\n<\/li>\n<li>\nProBioGen\n<\/li>\n<li>\nPT Etana Biotechnologies\n<\/li>\n<li>\nQilu Pharmaceutical\n<\/li>\n<li>\nQuanta BioDesign\n<\/li>\n<li>\nQuiaPEG Pharmaceuticals\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4636693\/global-biosimilars-partnering-terms-and?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=fn9hmn&amp;utm_campaign=1718434+-+Global+Biosimilars+Partnering+Terms+and+Agreements+2010+to+2022%3A+Featuring+Boston+Oncology%2C++Concord+Biosciences%2C+Horizon+2020+%26+More&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/35ddba<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;:&#x70;r&#101;&#x73;&#115;&#x40;&#114;&#x65;s&#x65;a&#114;&#x63;&#104;&#x61;&#110;&#x64;&#109;&#x61;r&#x6b;e&#116;&#x73;&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x65;&#x73;&#x73;&#64;&#114;&#101;&#115;ear&#x63;&#x68;&#x61;&#x6e;&#x64;&#x6d;&#97;&#114;&#107;ets&#x2e;&#x63;&#x6f;&#x6d;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Biosimilars Partnering Terms and Agreements 2010 to 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide. The report provides a detailed understanding and analysis of how &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45479","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Biosimilars Partnering Terms and Agreements 2010 to 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide. The report provides a detailed understanding and analysis of how ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-24T13:01:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220624005246\/en\/1496401\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-06-24T13:01:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/\"},\"wordCount\":787,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220624005246\\\/en\\\/1496401\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/\",\"name\":\"Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220624005246\\\/en\\\/1496401\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-06-24T13:01:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220624005246\\\/en\\\/1496401\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220624005246\\\/en\\\/1496401\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Biosimilars Partnering Terms and Agreements 2010 to 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide. The report provides a detailed understanding and analysis of how ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-24T13:01:45+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220624005246\/en\/1496401\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More &#8211; ResearchAndMarkets.com","datePublished":"2022-06-24T13:01:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/"},"wordCount":787,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220624005246\/en\/1496401\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/","name":"Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220624005246\/en\/1496401\/21\/logo.jpg","datePublished":"2022-06-24T13:01:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220624005246\/en\/1496401\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220624005246\/en\/1496401\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-biosimilars-partnering-terms-and-agreements-2010-to-2022-featuring-boston-oncology-concord-biosciences-horizon-2020-more-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 &amp; More &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45479"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45479\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}